Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter (Q1) ended March 31, 2020
Issuance Date: April 29, 2020
GSK reported strong Q1 2020 performance, driven by underlying business growth and increased demand/stock-building related to the COVID-19 pandemic. The company is actively developing adjuvanted COVID-19 vaccines in collaboration with partners including Sanofi and Vir Biotechnology.
Key Financial Metrics
| Metric | Q1 2020 | Q1 2019 | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £9.09 billion | £7.66 billion | +19% | +19% |
| Total Operating Profit | £2.01 billion | £1.43 billion | +41% | +42% |
| Adjusted Operating Profit | £2.68 billion | £2.16 billion | +24% | +24% |
| Total EPS | 31.5p | 16.8p | +87% | +89% |
| Adjusted EPS | 37.7p | 30.1p | +25% | +26% |
| Net Cash from Operations | £965 million | £663 million | +46% | - |
| Free Cash Flow | £531 million | £165 million | >100% | - |
| Net Debt | £26.67 billion | £27.06 billion | - | - |
Segment Performance (Turnover Growth CER):
- Pharmaceuticals: £4.40 billion (+6%)
- Vaccines: £1.81 billion (+19%)
- Consumer Healthcare: £2.86 billion (+46% reported; +11% pro-forma)
Material Changes vs. Prior Period
- Revenue Drivers: Growth was supported by strong performance in Respiratory products (Trelegy Ellipta +>100%, Nucala +38%) and Vaccines (Shingrix +81%). Consumer Healthcare saw significant reported growth due to the inclusion of the Pfizer portfolio, with pro-forma growth of 11% CER.
- Profitability: Adjusted operating margin improved to 29.4% (up 1.1 percentage points CER) due to operating leverage and a favorable product mix in Vaccines.
- One-off Items: Total EPS was significantly boosted by a non-recurring gain from the increase in value of shares in Hindustan Unilever (related to the Horlicks disposal) and a lower effective tax rate. Conversely, Total results were impacted by a £473 million charge for re-measurement of contingent consideration liabilities.
- Cash Flow: Free cash flow more than doubled, driven by improved operating profits and beneficial timing of payments for returns and rebates.
Guidance, Outlook, and Risks
- 2020 Guidance: GSK is maintaining its full-year 2020 Adjusted EPS guidance (decline of -1% to -4% at CER) based on current assessments. However, the company explicitly states it will update guidance if more information regarding the pandemic's impact becomes available.
- COVID-19 Impact: Management cites significant uncertainty regarding the pandemic's duration and severity. Risks include supply chain disruptions, clinical trial delays, and reduced patient access to elective treatments (notably vaccines like Shingrix).
- Liquidity: The company maintains a strong liquidity position with sufficient cash for operational needs and access to significant undrawn committed financing.
- Pipeline Highlights:
- Zejula: Submission accepted by FDA/EMA for ovarian cancer.
- Belantamab mafodotin: FDA priority review granted for multiple myeloma (PDUFA August 2020).
- Cabenuva: Approved in Canada; FDA reply expected mid-year.
- COVID-19: Multiple collaborations underway for adjuvanted vaccines and therapeutic antibodies.
Investor Verification Checklist
- Pro-forma Adjustments: Verify the distinction between reported Consumer Healthcare growth (+46%) and pro-forma growth (+11%) to understand the true organic performance post-Pfizer acquisition.
- Contingent Consideration: Review the £473 million re-measurement charge related to ViiV Healthcare and Novartis liabilities, as this significantly impacts Total vs. Adjusted results.
- Guidance Sensitivity: Monitor future updates to the 2020 Adjusted EPS guidance, as the current maintenance is conditional on the evolving COVID-19 situation.
- Stock Building Impact: Assess the sustainability of Respiratory and Consumer Healthcare sales growth, which was partially driven by pandemic-related stock building.
- Dividend Policy: Confirm the Board's intention to maintain the 2020 dividend at 80p per share, subject to external environment changes.